TEL AVIV, Israel--(BUSINESS WIRE)--Nov. 24, 2015--
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical
company dedicated to identifying, in-licensing and developing promising
therapeutic candidates, announced today that its Chief Executive
Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating
Officer, Philip Serlin, will be presenting at the LD
Micro Main Event on December 2, 2015. The presentation will take
place at 10:00 a.m. PST at the Luxe Sunset Boulevard Hotel in Los
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-8040, a cancer therapy platform,
which is in the midst of a Phase 2 study for relapsed/refractory AML,
has recently initiated a Phase 2b study as an AML consolidation
treatment, has recently initiated a Phase 1/2 study in hMDS and AA, and
has successfully completed a Phase 1 study in stem cell mobilization;
and BL-7010 for celiac disease, which has successfully completed a Phase
In December 2014, BioLineRx entered into a strategic collaboration with
Novartis for the co-development of selected Israeli-sourced novel drug
candidates. The companies intend to co-develop a number of pre-clinical
and early clinical therapeutic projects through clinical
proof-of-concept for potential future licensing by Novartis.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as the
Google Play Store.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151124005375/en/
Source: BioLineRx Ltd.
Vivian Cervantes, 212-554-5482
Tsipi Haitovsky, +972-3-624-0871